Abzena inks licence agreement with Trieza Therapeutics

22nd Dec 2016 14:20

(ShareCast News) - Life-sciences group Abzena has inked a licence agreement with start-up biotechnology company Trieza Therapeutics.US-based Trieza specialises in the discovery and development of immunomodulatory oncolytic viruses.Abzena has granted Trieza an exclusive licence to an undisclosed antibody sequence.The sequence was created using the group's composite human antibody technology, for exploitation in conjunction with Trieza's viral vector technology to develop novel therapies in oncology.The licence is worldwide, royalty bearing and sub-licensable.Abzena could receive up to $35m in development and commercial milestone payments as well as royalties on the sale of licensed products containing the Abzena sequence.At about 14:03 GMT, shares in AIM-quoted Abzena were up 3.76% to 34.5p.